Neurogene Reports Q1 Results, Strong Cash Position, and NGN-401 Trial Progress

summarizeSummary

Neurogene Inc. reported a widened Q1 net loss but highlighted a strong cash position expected to fund operations through Q1 2028, alongside significant progress in its NGN-401 registrational trial for Rett syndrome.

check_boxKey Events

• Q1 2026 Financials

  Reported a net loss of $30.9 million for Q1 2026, widened from $22.6 million in Q1 2025, primarily due to increased R&D expenses for the NGN-401 clinical trial.

• Extended Cash Runway

  Ended Q1 2026 with $243.2 million in cash, cash equivalents, and short-term investments, which is expected to fund planned operations through the first quarter of 2028.

• NGN-401 Trial Advancement

  Dosed approximately 90% of participants in the Embolden™ registrational trial for NGN-401 gene therapy for Rett syndrome, remaining on track to complete dosing in Q2 2026.

• Upcoming Clinical Data

  Anticipates presenting updated interim safety and efficacy data on the pediatric and adolescent/adult cohorts from the Phase 1/2 trial in mid-2026.

auto_awesomeAnalysis

This 8-K provides the official Q1 2026 financial results and significant operational updates for Neurogene. While the net loss widened, the company reported a strong cash position of $243.2 million, extending its operational runway through Q1 2028. This financial stability is crucial for a clinical-stage biotech. Additionally, the lead gene therapy candidate, NGN-401 for Rett syndrome, is making substantial clinical progress with 90% of participants dosed in its registrational trial, keeping it on track for completion in Q2 2026. Upcoming interim data in mid-2026 will be a key catalyst.